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Abstract
Aims/hypothesis Few studies examine the association between age at diagnosis and subsequent complications from type 2
diabetes. This paper aims to summarise the risk of mortality, macrovascular complications and microvascular complications
associated with age at diagnosis of type 2 diabetes.
Methods Data were sourced fromMEDLINE and All EBM (Evidence Based Medicine) databases from inception to July 2018.
Observational studies, investigating the effect of age at diabetes diagnosis on macrovascular and microvascular diabetes compli-
cations in adults with type 2 diabetes were selected according to pre-specified criteria. Two investigators independently extracted
data and evaluated all studies. If data were not reported in a comparable format, data were obtained from authors, presented as
minimally adjusted ORs (and 95%CIs) per 1 year increase in age at diabetes diagnosis, adjusted for current age for each outcome
of interest. The study protocol was recorded with PROSPERO International Prospective Register of Systematic Reviews
(CRD42016043593).
Results Data from 26 observational studies comprising 1,325,493 individuals from 30 countries were included. Random-effects
meta-analyses with inverse variance weighting were used to obtain the pooled ORs. Age at diabetes diagnosis was inversely
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age at diabetes diagnosis was associated with a 4%, 3% and 5% decreased risk of all-cause mortality, macrovascular disease and
microvascular disease, respectively, adjusted for current age. The effects were consistent for the individual components of the
composite outcomes (all p < 0.001).
Conclusions/interpretation Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and
vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and
cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality.
Keywords Age factors . Age of onset . Diabetes . Diabetes complications . Diabetes mellitus, type 2 . Disease progression .
Meta-analysis . Prognosis . Systematic review
Introduction
The IDF estimates that the prevalence of diabetes will rise
from 425 million people worldwide in 2017, to 629 million
by 2045 [1]. Type 2 diabetes, conventionally considered a
disease of middle and older age, is increasingly diagnosed at
a younger age [1, 2]. Type 2 diabetes and its associated
complications contribute to 8.4% of deaths worldwide,
consuming significant healthcare resources [3]; this is likely
to rise exponentially given the increasing prevalence of the
condition [1].
Despite significant diagnostic, monitoring and treatment
advances, type 2 diabetes remains associated with increased
mortality and morbidity compared with the general population
[4]. However, the pathogenesis of the long-term vascular
complications associated with early- or late-onset type 2
diabetes is not well characterised and although the mecha-
nisms for the development of complications may be similar
[5], recent evidence suggests an accelerated course in people
diagnosed with early-onset type 2 diabetes [6, 7]. Proposed
mechanisms include a longer lifetime exposure to the adverse
diabetic milieu and/or early-onset type 2 diabetes representing
an inherently more aggressive metabolic phenotype with rapid
onset of beta cell failure and insulin resistance compared with
late-onset disease [2, 8, 9]. Novel cluster analyses raise the
possibility of type 2 diabetes representing a clustering of up to
five disease subgroups with distinct age at diagnosis, genetics,
mechanisms of disease progression and risk of diabetic
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complications [10]. Of the five groups identified, the ‘mild
age-related diabetes’ subgroup contains elderly people who
experience the most benign disease course compared with
the ‘mild obesity-related diabetes’ group, characterised by
younger age at onset and obesity.
Several studies have examined the relationship between
age at diabetes diagnosis and long-term complications among
people with type 2 diabetes. These studies vary widely in
population characteristics and methodological rigour and
report inconsistent findings (e.g. younger age at diabetes diag-
nosis is associated with increased risk of complications [6, 7,
11–15], decreased risk of complications [16, 17], no differ-
ence in risk of complications [18] or variable effects in differ-
ent end organs [19, 20]). Additionally, some studies have
proposed that longer diabetes duration [21, 22] or more
adverse cardiovascular risk profiles [23, 24] underlie the
greater risk of development of vascular complications associ-
ated with type 2 diabetes diagnosed at a younger age, while
other studies have suggested that impact of age at diagnosis
may vary with ethnicity [25].
Evidence of a clinically meaningful effect of age at diag-
nosis of type 2 diabetes beyond the ageing process itself
would have substantial implications for diabetes prevention
and treatment as well as the development and implementation
of cardiovascular risk prediction tools. The aim of our study
was thus to examine the effect of age at diagnosis of type 2
diabetes on risks of complications, focusing on all-cause
mortality, macrovascular events and microvascular events.
Methods
Data sources and searches
A systematic search of published literature was conducted in
MEDLINE and All EBM (Evidence Based Medicine; www.
ovid.com/product-details.904.html) databases (including
Cochrane Database of Systematic Reviews, ACP Journal
Club Database of Abstracts of Reviews of Effects, Cochrane
Central Register of Controlled Trials, Cochrane Methodology
Register, Health Technology Assessment and NHS Economic
Evaluation Database) using the subject headings and key
terms detailed in electronic supplementary materials (ESM)
Methods. The study methods and reporting follow the Meta-
analyses Of Observational Studies in Epidemiology
(MOOSE) and Preferred Reporting Items for Systematic
review and Meta-Analysis (PRISMA) guidelines [26, 27].
The study protocol was recorded with PROSPERO interna-
tional prospective register of systematic reviews
(CRD42016043593). The search was limited to humans and
English language articles and was initially conducted in
July 2016 with no time restrictions and updated in July 2018.
Study selection
The inclusion criteria were determined a priori (ESMTable 1).
To be included, studies had to meet the following criteria: be a
study of adult participants with type 2 diabetes investigating
the effect of age at diabetes diagnosis on macrovascular and
microvascular diabetes complications; the study had to assess
one or more of the outcome variables all-cause mortality,
macrovascular disease, microvascular disease, retinopathy,
nephropathy, neuropathy, CVD, cerebrovascular disease and
peripheral vascular disease; the study had to have an available
mortality/complication rate, where mortality was either a pre-
specified primary or secondary outcome, or the methods indi-
cated complete follow-up of participants.
Two independent authors (NN and AMG) assessed
the title and abstracts of retrieved records for relevance
and duplication. Authors then reviewed the full text of
potentially eligible citations to identify studies that
fulfilled the inclusion criteria. Any uncertainties regard-
ing study inclusion and data extraction were discussed
with an experienced systematic reviewer (AJC), statisti-
cian (SH) and senior clinician (SZ). The references cited
in the retrieved publications were screened for potential-
ly eligible studies. When several articles from the same
study had reported on the same endpoint, only the data
representing the longest follow-up were extracted.
Data extraction and quality assessment
Data were extracted from included studies using a specially
developed data extraction form. Information was obtained
regarding study design and location, participant characteris-
tics, outcome variables and results. Given the wide variation
in data reporting and adjustment for confounders, meaningful
interpretation, comparison and meta-analysis was not possi-
ble. Therefore, we contacted authors to re-analyse and present
data in a homogeneous format to enable data pooling and
comparison. Corresponding authors were contacted by e-
mail at least twice (if data were not reported in a suitable
format) to request data, presented as minimally adjusted
ORs (95%CI) per 1 year increase in age at diabetes diagnosis,
with adjustment for current age (or diabetes duration) for each
outcome of interest. This format was chosen as most of the
studies presented the results in this way.
Risk of bias of included studies was assessed using a
specially developed data extraction form, based on the
Newcastle–Ottawa scaling for non-randomised studies [28,
29]. Quality assessment criteria included representativeness
of participants, validity of the diagnostic criteria, determina-
tion of age at diagnosis, outcome assessment, withdrawals and
losses to follow-up. Each study was then allocated a risk of
bias rating (ESM Tables 2, 3).
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Exposures
Current age was reported by each study as age at entry into the
study or age at baseline assessment. Age at type 2 diabetes
diagnosis was reported as the age of the people at the diagno-
sis of type 2 diabetes, with diabetes duration reported or calcu-
lated as current age minus age at diabetes diagnosis.
Outcomes
The primary a priori outcomes were all-cause mortality,
macrovascular disease (composite of CHD, cerebrovascular
disease and peripheral vascular disease) or microvascular
disease (composite of retinopathy, nephropathy and neuropa-
thy). The secondary a priori outcomes were retinopathy,
nephropathy, neuropathy, CHD, cerebrovascular disease and
peripheral vascular disease.
Statistical analysis
Interdependence of current age, age at diabetes diagnosis and
diabetes duration precluded use of all three variables in the
same model; hence the use of models containing either age at
diabetes diagnosis adjusted for current age or age at diabetes
diagnosis adjusted for diabetes duration. Adjustment for
current age was to remove the effect of ageing per se.
Adjustment for diabetes duration was to remove the effect of
the time point at which observations happened to be made in
the course of illness for each individual; an individual
observed early in their illness would appear to have a longer
time to develop complications than the same individual
observed late in their illness. For studies reporting in multiple
models, we extracted data for both minimally adjusted and
maximally adjusted increased risk estimates. Unless otherwise
stated, the least adjusted risk estimates from each study were
used, provided diabetes duration was included. Review
Manager (RevMan) software Version 5.3 was used for all
statistical analyses [30].
Data were combined in meta-analyses to calculate pooled
risk estimates presented as OR (95%CI) of the effect of age at
diabetes diagnosis (per year) adjusted for current age (or
diabetes duration [supplemental analyses]), on outcomes
using both fixed and random-effects models (generic inverse
variance method) [31]. There were no significant differences
between fixed- and random-effects analyses. Random-effects
models are presented given heterogeneity among the studies
[32]. Crude data were included where possible, given variable
control for confounding factors. However, some articles
presented adjusted ORs only.
I2 was used to assess heterogeneity with values of 25%,
50% and 75% considered low, moderate and high, respective-
ly [33]. Funnel plots were used to explore potential publica-
tion bias [34, 35]. A scatter plot of the t statistic associated
with each study-estimate value assessed the contribution of
each study to the study-estimate random effect vs the log10
of the SE of the effect.
Results
Characteristics of included studies
Electronic database and reference searching yielded 2219 publi-
cations, of which 156 were reviewed in full text (Fig. 1). Of 33
eligible studies, 26 studies comprising 1,325,493 individuals
were included and seven were excluded because data were
not provided in the required format in the publication and
attempts to contact authors were not successful. The 26 includ-
ed studies were either cross-sectional (13 studies) or cohort (13
studies) in design. The updated search in 2018 enabled the
inclusion of data from three studies. The mean age of study
participants ranged from 21.6 years to 67.4 years. The propor-
tion of female study participants ranged from 42.5% to 68.6%.
Table 1 summarises the characteristics of the included studies,
which comprise 1,325,493 participants from 30 countries
worldwide.
Primary outcomes
Effects of age at diabetes diagnosis adjusted for current age
on all-cause mortality, macrovascular disease and microvas-
cular disease For all-cause mortality, data from five studies
[20, 21, 25, 36, 37], comprising 1,325,493 participants, indi-
cated that each 1 year increase in age at diabetes diagnosis was
associated with a 4% decreased risk of all-cause mortality (OR
0.96 [0.94, 0.99], p < 0.001) when adjusted for current age.
Formacrovascular disease, data from eight studies [20, 23–25,
37–40], comprising 566 011 participants, indicated that each
1 year increase in age at diabetes diagnosis was associated
with a 3% decreased risk of macrovascular disease (OR 0.97
[0.96, 0.98], p < 0.001) when adjusted for current age. For
microvascular disease, data from eight studies [20, 24, 25,
38–42], comprising 149,110 participants, indicated that each
1 year increase in age at diabetes diagnosis was associated
with a 5% decreased risk of microvascular disease (OR 0.95
[0.94, 0.96], p < 0.001) when adjusted for current age.
Significant heterogeneity in the magnitude of the effects was
evident between studies for these outcomes (all χ2 p < 0.001,
all I2 ≥ 93%) (Fig. 2).
Secondary outcomes
Effects of age at diabetes diagnosis adjusted for current age
on CHD, cerebrovascular disease, peripheral vascular disease,
retinopathy, nephropathy and neuropathy Data for individu-
al vascular complications were available from 13 studies,
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comprising 566 011 participants and adjusted for current age.
Each 1 year increase in age at diabetes diagnosis was associ-
ated with a 2% decreased risk of CHD (OR 0.98 [95% CI
0.97, 0.98], p < 0.001), a 2% decreased risk of cerebrovascular
disease (OR 0.98 [95% CI 0.97, 0.99], p < 0.001) and a 3%
decreased risk of peripheral vascular disease (OR 0.97 [95%
CI 0.96, 0.99], p < 0.001) (Fig. 3). Each 1 year increase in age
at diabetes diagnosis was associated with an 8% decreased
risk of retinopathy (OR 0.92 [95% CI 0.90, 0.95],
p < 0.001), a 6% decreased risk of nephropathy (OR 0.94
[0.92, 0.96], p < 0.001) and a 5% decreased risk of neuropathy
(OR 0.95 [95% CI 0.94, 0.96], p < 0.001) (Fig. 3). Significant
heterogeneity in the magnitude of the effects was evident
between studies for these outcomes (all χ2 p < 0.001, all
I2 ≥ 48%).
Sensitivity analyses
Effects of age at diabetes diagnosis adjusted for diabetes
duration on all-cause mortality, macrovascular disease and
microvascular disease Data for these analyses were obtained
from ten studies comprising 390,139 participants and adjusted
for diabetes duration (ESM Fig. 1). Each 1 year increase in age
at diabetes diagnosis was associated with a 6% increased risk of
all-cause mortality (OR 1.06 [95% CI 1.03, 1.09], p < 0.001), a
6% increased risk of macrovascular disease (OR 1.06 [95% CI
1.04, 1.07], p < 0.001) and a 5% increased risk ofmicrovascular
disease (OR 1.05 [95% CI 1.02, 1.08], p < 0.001).
Methodological quality
Risk of bias assessment of the included studies is presented in
ESMTable 3. Study participants were recruited to randomised
clinical trials or selected from large clinical datasets. Inclusion
and exclusion criteria were adequately described in all studies.
Of the included studies, 24 [14, 15, 20, 21, 23–25, 36–52]
were of high quality and two [53, 54] of medium quality due
to insufficient adjustment of confounding variables. In addi-
tion, 24 studies [14, 15, 20, 21, 23–25, 36–52] demonstrated
low risk of bias and two [53, 54] demonstrated a moderate risk
of bias due to insufficient adjustment for confounding vari-
ables (confounding bias) (ESM Table 3). Funnel plots did not
suggest the presence of publication bias (ESM Fig. 2).
Discussion
This comprehensive systematic review and meta-analysis
compiles the results of 26 studies investigating the effects of
age at diabetes diagnosis on mortality and subsequent compli-
cations in 1,325,493 participants with type 2 diabetes from
diverse populations across the Asia Pacific, Europe and
North America. We report an inverse relationship between
age at diabetes diagnosis and risk of major diabetes complica-
tions after adjustment for current age. Each 1 year increase in
age at diabetes diagnosis was associated with a 4%, 3% and
5% decreased risk of all-cause mortality, macrovascular
disease and microvascular disease, respectively. These effects
were consistent across the individual components of the
composite outcomes (CHD, cerebrovascular disease, periph-
eral vascular disease, retinopathy, nephropathy and neuropa-
thy) and reversed when the models included diabetes duration
rather than current age.
While earlier studies have assessed the effects of age at
diabetes diagnosis on diabetes complications, to our knowl-
edge, this is the first systematic review and meta-analysis
exploring associations between age at diabetes diagnosis and
subsequent outcomes. Interdependence of current age, age at
diabetes diagnosis and diabetes duration precluded investiga-
tion of all three variables simultaneously; hence the use of
models containing either age at diabetes diagnosis adjusted
for current age or age at diabetes diagnosis adjusted for
Studies idenfied by main search 
(N=2219) 
Studies retrieved for full text review
(n=156) 
Studies included in the systemac 
review (n=26) 
Studies excluded on review of tle/abstract 
(n=2063) 
Studies excluded aer full text review (n=130)
Data not available (7)
Lack of complicaon data (13)
Reviews, leers or editorials (17)
Mulple arcles on same dataset (6)
Lack of age at diabetes onset informaon (31)
No analyses by age at diabetes onset (31)
No separate data for type 1 and 2 diabetes (10)
No comparison between old and young paents (15)






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































diabetes duration. People diagnosed with diabetes at an older
age may be more likely to have accumulated adverse cardio-
vascular risk factors compared with those diagnosed at a
younger age. Since advancing age is a powerful predictor of
vascular complications, for the same diabetes duration, people
diagnosed at a younger age are likely to have lower absolute
risks of events as compared with people diagnosed at an older
age. Over time, however, the effects of both ageing and
disease duration may be amplified, resulting in premature
complications and death in people diagnosed with type 2
diabetes at a younger age. To illustrate, a person diagnosed
with type 2 diabetes at age 30 years would have a lower
absolute risk of complications compared with a person diag-
nosed at age 50 years but by the time they both reach age
60 years the person diagnosed at a younger age would have
a higher relative and absolute risk due to the effects of ageing,
compounded by the effects of longer diabetes duration. This
pattern has been observed in several young-onset type 2
diabetes populations [21, 55]. Thus, younger people pose a
significant challenge for clinicians and decision makers who
need to be aware of these compounding pathologies of natural
ageing and premature vascular ageing associated with type 2
diabetes. Further, people diagnosed with type 2 diabetes at a
younger age still have the potential to develop complications
at an earlier stage of life, at a time when the complications are
more likely to cause greater disability and loss of productivity
compared with people diagnosed at an older age.
There is a lack of RCT studies on achieving good
glycaemic control and optimisation of cardiovascular risk
factors in young-onset type 2 diabetes; many trials recruited
middle-aged people with long disease duration at greatest
absolute risk of complications. However, data from these
older populations may not reflect the pathophysiology of type
2 diabetes in younger people, given evidence suggesting that
the development of diabetes complications may differ
between younger and older individuals. Further, many of
these studies lack sufficient follow-up to capture complica-
tions in younger people who may have a longer time to event.
The observations of this study and others examining type 2
diabetes complications [15, 23, 38, 51] add impetus to
conducting trials examining this young cohort. There is an
urgent need for data specifically pertaining to younger type
2 diabetes populations examining the trajectory of vascular
complications and the impact of interventions (pharmacolog-
ical as well as non-pharmacological approaches) to improve
outcomes.
We found that age at diabetes diagnosis adjusted for current
age was inversely associated with risk of all-cause death,
Outcome OR (95%CI) n
All-cause mortality
Huo, L., et al [52] 0.95 (0.95, 0.96) 744,188
Kenealy, T., et al [25] 0.98 (0.97, 0.99) 70,057
Pavkov, M.E., et al [21] 0.90 (0.89, 0.92) 2963
Penno, G., et al [36] 0.99 (0.99, 0.99) 15,733





=98%) 0.96 (0.94, 0.99) 844,081
Macrovacular disease
Chan, J.C., et al [38] 0.92 (0.91, 0.93) 9506
Huo, X., et al [37] 0.97 (0.97, 0.97) 222,770
Kenealy, T., et al [25] 0.97 (0.97, 0.98) 48,444
Nanayakkara, N., et al [39] 0.97 (0.96, 0.98) 3029
Pugliese, G., et al [40]
0.99 (0.98, 0.99)
15,933
Song, S.H., Hardisty C.A. [23] 0.98 (0.97, 0.99) 2,733
Yeung, R.O., et al [24] 0.97 (0.97, 0.97) 42,453
Zoungas, S., et al [20] 0.97 (0.96, 0.98) 11,140
Overall (p<0.001, I
2
=97%) 0.97 (0.96, 0.98) 356,008
Microvascular disease
Amutha A., et al [41] 1.12 (0.98, 1.27) 90
Chan, J.C., et al [38] 0.98 (0.97, 0.99) 9506
Kenealy, T., et al [25] 0.96 (0.95, 0.96) 65,547
Nanayakkara, N., et al [39] 0.93 (0.92, 0.93) 3033
Pradeepa R., et al [42] 0.91 (0.88, 0.95) 1608
Pugliese, G., et al [40] 0.96 (0.95, 0.96) 15,733
Yeung, R.O., et al [24] 0.95 (0.95, 0.96) 42,453









Fig. 2 Effect of age at diagnosis
(per 1 year increase), adjusted for
current age on the risk of all-cause
mortality, macrovascular disease
and microvascular disease. The
size of the symbols is proportional
to the study weight and horizontal
lines represent 95% CIs
Diabetologia
macrovascular disease and microvascular disease. Our find-
ings underscore the importance of cardiovascular risk
management among people with diabetes. Screening for and
prevention of macrovascular complications is particularly
important for older people with diabetes, who have the highest




Amutha A., et al [41] 1.04 [0.88, 1.22] 90
Amutha, A., et al [43] 0.89 [0.83, 0.96] 840
Kenealy, T., et al [25] 0.96 [0.95, 0.96] 66,128
Nanayakkara, N., et al [39] 0.95 [0.94, 0.97] 2970
Pavkov, M.E., et al [21] 0.90 [0.88, 0.91] 2726
Romero-Aroca, P., et al [48] 0.90 [0.89, 0.92] 15,030
Unnikrishnan, R, Anjana RM., et al [51] Older onset* 0.95 [0.85, 1.06] 267
Unnikrishnan, R, Anjana RM., et al [51] Younger onset* 0.97 [0.87, 1.08] 173
Unnikrishnan, R, Rema M., et al [52] 0.97 [0.95, 0.99] 267
Zoungas, S., et al [20] 0.96 [0.95, 0.97] 11,140
Overall (p<0.001, I
2
=92%) 0.94 [0.92, 0.96] 99,631
Neuropathy
Amutha A., et al [41] 0.87 [0.71, 1.07] 90
Amutha, A., et al [43] 0.91 [0.83, 1.00] 672
Kenealy, T., et al [25] 0.96 [0.95, 0.96] 65,906
Nanayakkara, N., et al [39] 0.95 [0.94, 0.96] 3358
Pradeepa R, Rema M., et al [45] 0.97 [0.95, 0.99] 1629
Song, S.H. and C.A. Hardisty [23] 0.94 [0.93, 0.95] 2733
Unnikrishnan, R, Anjana RM., et al [51] Older onset* 1.05 [0.84, 1.31] 256
Unnikrishnan, R, Anjana RM., et al [51] Younger onset* 1.05 [0.84, 1.31] 240
Overall (p<0.001, I
2
=48%) 0.95 [0.94, 0.96] 74,884
Retinopathy
Amutha A., et al [41] 0.87 [0.71, 1.07] 90
Amutha, A., et al [43] 0.91 [0.85, 0.98] 743
Cai, X., et al. [14] 0.90 [0.88, 0.91] 3100
Chen, M.S., et al 53] 0.99 [0.89, 1.10] 527
Huo, X., et al [37] 0.91 [0.86, 0.95] 222,770
Kenealy, T., et al [25] 0.91 [0.86, 0.96] 67,739
Nanayakkara, N., et al [39] 0.92 [0.91, 0.93] 3261
Pugliese, G., et al [40] 1.01 [1.00, 1.03] 15,933
Rema, M., et al [46] 0.90 [0.88, 0.92] 1715
Romero-Aroca, P., et al [48] 0.91 [0.89, 0.94] 15,030
Song, S.H. and T.A. Gray [49] 0.86 [0.75, 0.98] 2516
Thomas, R.L et al [49] 0.90 [0.90, 0.90] 152,156
Unnikrishnan, R, Anjana RM., et al [50] Older onset* 0.89 [0.83, 0.95] 240
Unnikrishnan, R, Anjana RM., et al [50] Younger onset* 0.86 [0.75, 0.98] 177
Wong, J., et al [15] 0.94 [0.93, 0.95] 1476
Zoungas, S., et al [20] 0.97 [0.96, 0.98] 11,140
Overall (p<0.001, I
2
=97%) 0.92 [0.90, 0.95] 498,613
Coronary heart disease
Kenealy, T., et al [25] 0.97 [0.96, 0.98] 59,228
Nanayakkara, N., et al [39] 0.98 [0.97, 0.99] 3037
Pugliese, G., et al [40] 0.98 [0.97, 0.98] 15,733
Song, S.H. and C.A. Hardisty [23] 0.99 [0.98, 1.01] 2733
Zoungas, S., et al [20] 0.98 [0.97, 0.99] 11,140
Overall (p<0.001, I
2
=54%) 0.98 [0.97, 0.98] 91,871
Cerebrovascular disease
Kenealy, T., et al [25] 0.98 [0.97, 0.99] 66,292
Nanayakkara, N., et al [39] 0.98 [0.97, 1.00] 2982
Pugliese, G., et al [40] 0.96 [0.96, 0.97] 15,933
Song, S.H. and C.A. Hardisty [23] 0.97 [0.95, 0.99] 2733
Zoungas, S., et al [20] 0.98 [0.97, 0.99] 11,140
Overall (p<0.001, I
2
=75%) 0.98 [0.97, 0.99] 99,080
Peripheral vascular disease
Amutha A., et al [41] 2.26 [0.12, 42.25] 672
Kenealy, T., et al [25] 0.96 [0.95, 0.98] 65,906
Nanayakkara, N., et al [39] 0.97 [0.95, 0.98] 3353
Pradeepa R, Chella S., et al [44] 1.02 [0.99, 1.05] 1755
Pugliese, G., et al [40] 0.96 [0.95, 0.96] 15,733
Song, S.H. and C.A. Hardisty [23] 0.95 [0.93, 0.97] 2733
Unnikrishnan, R, Anjana RM., et al [50] Older onset* 0.99 [0.89, 1.10] 258
Unnikrishnan, R, Anjana RM., et al [50] Younger onset* 1.19 [0.70, 2.04] 244
Zoungas, S., et al [20] 0.99 [0.98, 1.00] 11,140
Overall (p<0.001, I
2
=82%) 0.97 [0.96, 0.99] 101,794
Fig. 3 Effect of age at diagnosis (per 1 year increase), adjusted for current
age on the risk of secondary outcomes. The symbols are proportional to
the study weight and horizontal lines represent 95% CIs. For
Unnikrishnan, R, Anjana RM., et al [50], older onset refers to those
diagnosed aged >50 years and younger onset refers to those diagnosed
aged ≤25 years
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most important risk factors for the development of
macrovascular complications. However, it is also important
to note that people diagnosed with diabetes at a younger age
have a longer lifetime risk of developing significant compli-
cations, thus achieving good glycaemic control and optimisa-
tion of cardiovascular risk factors is of particular importance
across their lifespan. This difference in risk between younger
and older people in terms of absolute vs lifetime risks of type 2
diabetes complications, should perhaps be recognised in
diabetes management guidelines, with increased promotion
of screening programmes in older people with type 2 diabetes
and a greater emphasis on preventive measures for younger
people with type 2 diabetes.
As early intensive multifactorial risk factor intervention is
important for the prevention of long-term macrovascular
complications among people with newly diagnosed diabetes
[56], our findings further suggest that this should be sustained
long-term to minimise risks over time. Clearly, strategies are
needed to ensure sustained adherence to lifestyle behaviours
and therapies proven to have cardiovascular benefits among
people with diabetes. Existing treatment guidelines are limited
by being reactive to suboptimal glycaemic control after it has
developed, without means to predict which people require
intensified treatment. Refined stratification using age at diag-
nosis may provide a method of identifying, at diagnosis, those
at greatest risk of complications who would most benefit from
targeted, individualised treatment regimens. Moreover, public
health measures to delay and/or prevent the onset of type 2
diabetes until older age may yield benefits by reducing the
duration of diabetes and the burden of complications.
The development and progression of type 2 diabetes repre-
sents a complex interplay between genetic, epigenetic, life-
style, demographic, socioeconomic, therapeutic and environ-
mental factors. Given the myriad factors involved, and the
variable reporting across included studies, it was difficult to
establish uniformity in study definitions and covariate adjust-
ment across studies. There was considerable variation in the
definitions of ‘younger’ and ‘older’ age at type 2 diabetes
diagnosis, with some studies defining ‘younger’ as >30 years
of age, >40 years of age or >50 years of age. To mitigate this,
we examined the effect of age at diabetes diagnosis (adjusted
for current age), in yearly increments. Studies varied greatly
with respect to measured confounding factors such as ethnic-
ity, study country and year, type 2 diabetes diagnostic criteria,
medication use, glycaemic control age, obesity, cardiometa-
bolic risk factors, comorbid conditions, recruitment, source of
participants, family history, healthcare access and
sociodemographic factors. We were unable to adjust for these
factors, as the data were either unavailable or not comparable
due to the lack of standardised definitions across published
studies. Moving forward, standardised approaches to
reporting and complete data capture of relevant variables will
assist with pooling and analysis of disparate datasets. This
may be facilitated by the creation of international data regis-
tries. Performance bias (a potential difference in the care
provided between early- and later-onset type 2 diabetes groups
and between different centres) could not be assessed. Older
people with type 2 diabetes may have cognitive impairment or
other comorbidities precluding treatment intensification or
even leading to de-intensification. Alternatively, people diag-
nosed with type 2 diabetes at a younger age may have been
treated more intensively than people diagnosed at an older
age. If this were the case, this bias would ameliorate the differ-
ences between groups, such that our data may actually under-
estimate the true extent of the effect of younger age at type 2
diabetes diagnosis. However, this appears less likely as sever-
al studies suggest that younger people with type 2 diabetes
have poorer glycaemic control, lower adherence to therapy
and inferior self-care practices compared with older people
[57, 58]. In fact, the data suggest that younger people with
type 2 diabetes receive suboptimal medical attention, poten-
tially due in part to an absence of clinical guidelines targeted
to younger people with type 2 diabetes and possibly the under-
estimation of risks of complications in these individuals [38].
The strength of this meta-analysis is the extensive and
comprehensive literature search and focus on studies examin-
ing younger and older people with type 2 diabetes. Six data-
bases were searched, a risk of bias appraisal performed, and
reanalyses were undertaken, enabling inclusion of data from
more than a million people with type 2 diabetes worldwide.
Collaboration with other authors facilitated more homoge-
neous data definitions, data integration and meta-analysis.
We found that there was high concordance between the differ-
ent studies included in the meta-analysis, such that the direc-
tions of the effects were consistent, although the magnitude of
effects and the CIs varied. This may be due to differences in
study size, although contributions from genetic, ethnic and
healthcare variations in study populations cannot be excluded.
Nevertheless, the direction of the effects was consistent across
the studies from different countries.
As with many systematic reviews and meta-analyses, this
meta-analysis has some limitations. Not all identified studies
were included in the meta-analysis due to difficulties sourcing
comparable data from authors. The inability to acquire data from
all eligible studies is not unexpected and is a part of the meta-
analysis process [59].We based our classification of age at type 2
diabetes diagnosis on the definitions used in each individual
study, even though these definitions may have differed. It would
be impossible to apply retrospectively a single definition of age at
diagnosis to a large number of samples characterised with differ-
ent variables in different studies. Additionally, the criteria for the
diagnosis and classification of type 2 diabetes have changed with
the advent of new technologies, such as the determination of
pancreatic autoantibodies and C-peptide levels, as have the
methods used to differentiate type 2 diabetes from other forms
of diabetes (principally type 1 and monogenic diabetes). Lastly,
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due in part to the nature of the study question, the included
studies were observational in design and therefore subject to
the potential biases (confounding and selection) inherent to anal-
yses of observational data. However, meta-analyses of observa-
tional studies can provide valuable insights, especially when
RCTs are unavailable or are inappropriate for addressing the
question [34], as is the case here. Findings from this review are
based on observational data and therefore causality may not be
attributed. Thus, although these findings may be applicable on a
population level, any recommendations need to be individualised
to the clinical situation of each person with type 2 diabetes.
We have completed the first systematic review and meta-
analysis examining the effects of age at type 2 diabetes diag-
nosis on all-cause mortality, microvascular complications and
macrovascular complications. This comprehensive analysis,
comprising over a million participants, indicates that when
adjusted for current age, younger age at type 2 diabetes diag-
nosis is associated with increased risk of mortality,
macrovascular complications and macrovascular compli-
cations. Identification and quantification of the increased
risk of mortality and vascular disease conferred by youn-
ger age at type 2 diabetes diagnosis may enable risk
stratification of people early in the condition and thereby
provide greater opportunities for interventions to reduce
risk of complication-associated morbidity and mortality
for this increasing population demographic developing
type 2 diabetes.
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